148
Participants
Start Date
July 1, 2015
Primary Completion Date
September 4, 2018
Study Completion Date
February 21, 2019
Entospletinib
Tablet(s) administered orally every 12 hours
Daunorubicin
60 mg/m\^2 administered intravenously daily on Days 1 to 3 for up to two 14-day induction cycles
Cytarabine
100 mg/m\^2 administered intravenously daily on Days 1 to 7 for up to two 14-day cycles
Decitabine
20 mg/m\^2 administered intravenously
Azacitidine
75 mg/m\^2 administered intravenously or subcutaneously
Universitätsklinikum Frankfurt Medizinische Klinik II, Frankfurt
Oregon Health & Science University, Portland
UCLA, Los Angeles
University of Chicago, Chicago
Loyola University Medical Center, Maywood
Indiana University, Indianapolis
University of Kansas Medical Center Research Institute, Inc, Fairway
Dana Farber Cancer Institute, Boston
Henry Ford Health System, Detroit
Karmanos Cancer Institute, Detroit
Weill Cornell Medical College - New York - Presbyterian Hospital, New York
Duke Cancer Center, Durham
University Hospitals Case Medical Center, Cleveland
Ohio State University, Columbus
Saint Francis Cancer Center, Greenville
Princess Margaret, Toronto
Jewish General Hospital, Montreal
Lead Sponsor
Gilead Sciences
INDUSTRY